FDA Approves Livsayis (cemdisiran) for the Treatment of Generalized Myasthenia Gravis

Nov 19, 2026 - 04:00
 0  0
TARRYTOWN, N.Y., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis (cemdisiran) for the treatment of generalized myasthenia gravis...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0